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Abstract
Background: Health equity concerns the absence of avoidable and unfair differences in health. Randomized
controlled trials (RCTs) can provide evidence about the impact of an intervention on health equity for specific
disadvantaged populations or in general populations; this is important for equity-focused decision-making.
Previous work has identified a lack of adequate reporting guidelines for assessing health equity in RCTs. The
objective of this study is to develop guidelines to improve the reporting of health equity considerations in
RCTs, as an extension of the Consolidated Standards of Reporting Trials (CONSORT).
Methods/design: A six-phase study using integrated knowledge translation governed by a study executive
and advisory board will assemble empirical evidence to inform the CONSORT-equity extension. To create the
guideline, the following steps are proposed: (1) develop a conceptual framework for identifying “equity-relevant trials,”
(2) assess empirical evidence regarding reporting of equity-relevant trials, (3) consult with global methods and
content experts on how to improve reporting of health equity in RCTs, (4) collect broad feedback and prioritize
items needed to improve reporting of health equity in RCTs, (5) establish consensus on the CONSORT-equity
extension: the guideline for equity-relevant trials, and (6) broadly disseminate and implement the CONSORT-equity
extension.
Discussion: This work will be relevant to a broad range of RCTs addressing questions of effectiveness for strategies to
improve practice and policy in the areas of social determinants of health, clinical care, health systems, public health,
and international development, where health and/or access to health care is a primary outcome. The outcomes
include a reporting guideline (CONSORT-equity extension) for equity-relevant RCTs and a knowledge translation
strategy to broadly encourage its uptake and use by journal editors, authors, and funding agencies.
Keywords: Randomized controlled trials, Cluster randomized control trials, Health equity, Reporting guidelines,
Methods, Health systems, Policy
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Background
Health equity is defined as the absence of avoidable and
unfair differences in health within and between popula-
tions [1] and is at the core of global health research prior-
ities [2, 3]. The concept of health equity includes both
access to health care as well as the broader concept of
opportunities to achieve good health [4–6]. While there is
a lack of consensus on the use of the terms health equity,
health inequality, and health disparities, we have chosen
the term “health equity” [7]. We consider differences in
health outcomes across socially stratifying factors such as
age, sex/gender, culture, and socioeconomic status to be
health inequities when they are considered avoidable and
unfair (Table 1). Absent and/or poor quality evidence
about health equity is identified by policy makers as a key
limitation of research [8, 9]. For example, evidence about
poor or black or Hispanic populations is missing in
reviews used for drug formulary development in the USA
[10]. To address key public health objectives, decision-
makers require the best evidence to guide appropriate
consideration of the likely effects on health equity in their
populations [3, 11, 12].
Randomized controlled trials (RCTs) are a powerful
research design for ascertaining the impact of an
intervention and for informing health decisions [13].
There is growing support for well-conducted RCTs to
improve the evidence base for the growing field of
personalized medicine [14] as well as population and
public health [15] and international development [16].
We define RCTs that meet one (or more) of the fol-
lowing criteria as “equity-relevant trials”: (1) assessing
effects in a disadvantaged population in relation to a
less disadvantaged population (see Table 1), (2) asses-
sing differences in effects between populations consid-
ered disadvantaged compared to a less disadvantaged
group (see Table 1), or (3) assessing gradient of ef-
fects across levels of disadvantage.
There are a number of challenges to overcome if
RCTs are to contribute to a robust evidence base for
policy making that promotes health equity across pop-
ulations [17, 18]. There is well-documented under-
representation of populations in RCTs who may be
disadvantaged due to their ethnicity within a popula-
tion, or their age, or gender. Even when these groups
are included in RCTs, the authors of the trials often
fail to report basic sociodemographic details [19] and
rarely are subgroup analyses conducted across
PROGRESS-Plus characteristics [20, 21]. All too often,
this makes it impossible to apply results to popula-
tions with particular characteristics or features. Clus-
ter RCTs pose additional challenges when assessing
effects on health equity because clusters may include
individuals experiencing disadvantage and/or clusters
may have different overall experience of disadvantage.
Systematic reviews are completely dependent upon the
constituent studies, so poor reporting of equity in
RCTs is a major constraint on equity assessment in
systematic reviews, as has been described frequently
but specifically in PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses)-equity
reporting guidelines [22].
Developing a CONSORT reporting guideline for equity
informing trials
The Consolidated Standards for Reporting Trials
(CONSORT) statement is an evidence-based guideline
consisting of 25 items, intended to encourage com-
pleteness and transparency of reporting RCTs. CON-
SORT has been endorsed by over 50 % of the
medical journals indexed in PubMed and has been
shown by a systematic review to improve reporting
[23]. CONSORT extension statements have been de-
veloped for specific issues, such as reporting of clus-
ter RCTs, harms, pragmatic trials, non-pharmacologic
therapy, and social and psychological interventions
[24]. None of the existing or planned CONSORT ex-
tensions addresses reporting characteristics needed to
Table 1 Defining health inequity and disadvantage
Health inequalities have been defined as “the virtually universal
phenomenon of variation in health indicators … associated with
socio-economic status” [50]; inequities may also be seen across other
characteristics such as place of residence, ethnicity, gender, etc.
Health inequities “are unnecessary, avoidable, unfair, and remediable
inequalities” [1, 51, 52]
The characteristics of populations and individuals across which health
inequities may exist are multifactorial and may interact with each other.
They may also depend on setting and context such as the political
climate or health system [17]. Different classification systems have been
developed to summarize these characteristics of individuals and
populations across which potentially inequitable health differences may
exist. Although different factors commonly co-exist, we are using the
PROGRESS-Plus organizing framework used by the Cochrane and
Campbell Equity Methods Group. The acronym PROGRESS represents:
place of residence, race/ethnicity/culture/language, occupation, gender/
sex, religion, education, socioeconomic status, and social capital [53, 54].
Additional “Plus” characteristics include (1) individual characteristics (e.g.,
age, disability), (2) features of relationships (e.g., parents who smoke),
and (3) time-dependent transitions (e.g., post-discharge from hospital or
prison) [54–56]. Differences in health across these groups do not necessarily
denote inequities. For example, increasing cancer incidence with age is not
necessarily unfair nor avoidable. However, preferential treatment for younger,
fitter people with cancer may be discriminatory [57].
We use the term “disadvantaged” to describe populations who are
denied opportunities that others have to benefit from social and
environmental conditions that lead to better health. A limitation of the
term disadvantaged is that it may be seen as labeling or stigmatizing
and it is a term that may not be used by populations or communities to
describe their contexts or situations. Many alternative terms are also
limited (e.g., underserved or marginalized) because they exclude other
population groups. Commitment to health equity is about improving
health outcomes for people who have been disadvantaged by social,
political, and legal structures, and processes in achieving good health.
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assess the effects of an intervention on health equity
(Appendix A).
Objectives
The main objective of this study is to develop guide-
lines to improve the reporting of health equity con-
siderations in RCTs, as an extension of CONSORT.
This program of research aims to meet the following
specific objectives, each of which aligns with a study
phase (Fig. 1):
1. To develop a conceptual framework for identifying
equity-relevant trials.
2. To assess empirical evidence regarding reporting of
equity-relevant trials.
3. To consult with global methods and content experts
on how to improve reporting of health equity in
RCTs.
4. To collect broad feedback and prioritize items
needed to improve reporting of health equity in
RCTs.
5. To establish consensus on the CONSORT-equity
extension: a reporting guideline for equity-relevant
trials.
6. To broadly disseminate and implement the
CONSORT-equity extension.
Methods/design
The study consists of six phases, adapted from the
guidance for developing reporting guidelines by Moher
et al. [25]. These are identifying the need for the guide-
line, reviewing the literature, identifying participants,
conducting a Delphi survey to gather opinions and set
priorities, and holding a face-to-face consensus meet-
ing. There will be two additions to these methods: (1) a
review of guidance from research ethics boards and
funding agencies about equity, inclusion, and diversity,
and (2) consultation using key informant interviews
across a broad range of disciplines to gather views on
how to improve reporting of effects in subpopulations
in RCTs (Fig. 1).
Ensuring the uptake of the CONSORT-equity exten-
sion is critical in order to influence reporting of future
trials. Therefore, we are using an integrated knowledge
translation approach that engages knowledge users as
partners throughout the process and as a way to foster
thinking about, inclusion, and respect for a multiplicity
of perspectives [26]. The co-authors represent a range of
PHASE 2: To assess empirical evidence on reporting of equity-
relevant trials
1.  Systematic review of methods to provide evidence about equity
2.  Empirical studies of methods used in equity-relevant trials
3.  Review of funding and ethical guidance
PHASE 3: To consult with global methods and equity experts on 
how to improve reporting of health equity in RCTs
PHASE 4: To collect broad feedback and prioritize items needed to 
improve reporting of health equity in RCTs - using a modified Delphi
process with a wide audience on importance and priority of candidate 
reporting items
PHASE 6: Disseminate CONSORT Equity extension - knowledge 
translation plan to reach specific audience, publications and 
presentations to a broad range of audience
PHASE 1: Conceptual framework.  To create a conceptual framework 
for identifying “equity-relevant trials”, that is, trials that contribute 
evidence about equity
Integrated
Knowledge 
Translation:
Advisory groups
Consensus 
methods
Communication
Strategy
PHASE 5: Establish consensus on CONSORT Equity - face to face
consensus conference 
Fig 1 CONSORT-equity: study phases
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disciplines including clinical epidemiology, social sci-
ence, public health, and international development and
are consulted regularly through quarterly meetings. We
have developed an international advisory board from
intended users across a range of perspectives: journal ed-
itors, trialists, bioethicists, patients and members of the
public, clinicians, systematic review authors, policy
makers, members of disadvantaged populations, and
funders (Appendix B). Completion of all study objectives
is anticipated by December 2017.
Phase 1: Development of a conceptual framework
We will use an iterative process to develop a conceptual
framework for identifying equity-relevant RCTs. To
date, we have consulted within the research team and
advisory board and reviewed conceptual papers [27–31]
to develop a draft conceptual framework (Fig. 2). We
tested this framework on sample trials with subgroup
analyses across one or more PROGRESS-Plus charac-
teristic and trials conducted in populations who may be
disadvantaged in some settings including children,
older adults, and individuals with lower income identi-
fied by searching PubMed.
We acknowledge that although most health condi-
tions exhibit a gradient of worse health for those ex-
periencing more disadvantage and conventionally
described or analyzed using socioeconomic variables
such as ethnicity and educational attainment [32],
many RCTs have not been powered or designed to
provide evidence about health equity; often, feasibility
and cost are used as defining reasons. Studies are to
be considered for inclusion if they provide estimates
of these effects, regardless of the sample or method
used to do so. In addition, the appropriateness of sam-
ple and method will be assessed as part of the study.
We will consider RCTs to be “equity-relevant” if they
provide evidence about the following:
(1)Effects in a population considered to be
disadvantaged,
(2)Difference or equivalence in effects across socially
stratifying factors, or
(3)Gradient of effects across socially stratifying factors.
The first criterion provides direct evidence about
health equity by comparing effects across strata of disad-
vantage. The latter two criteria provide indirect evidence
about health equity because there is no comparison to a
more advantaged population (Table 2). This framework
aligns closely with the framework by Hilary Graham that
categorizes three approaches to tackling health inequal-
ities and their implications for evaluation [27]. Further-
more, differences in effects may be assessed by different
methods ranging from subgroup analyses to assessing
external validity to populations not included in the trial
(e.g., many disadvantaged groups are excluded from tri-
als because of restrictive eligibility criteria such as pres-
ence of co-morbidities or age).
PHASE 1: Conceptual framework to identify “Equity-relevant trials”
Is the trial equity-relevant and provides 
evidence about PROGRESS+ criteria?
No evidence about equity Equity-relevant evidence
Provides evidence of 
effects in a population 
considered to be 
disadvantaged
Provides evidence of 
differences/ similarities 
of effects
Provides evidence of 
gradient of effects
YESNO
Fig. 2 Conceptual framework for identification of equity-relevant trials
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We will test the clarity, acceptability, and feasibility of
using this conceptual framework by discussing sample
trials with three types of stakeholders:
1. Advisory board members (Appendix B)
2. Investigators of effectiveness trials committed to
informing equity
3. Community representatives from disadvantaged
populations
This may result in additional changes to the concep-
tual framework.
Phase 2: Assessing the evidence
We will address three research questions about the
strengths and limitations of methods used to provide
evidence about equity in RCTs as well as existing guid-
ance regarding the use of these methods:
1. What are the strengths and limitations of methods
used in equity-relevant trials?
2. What is the existing guidance on conducting equity-
relevant trials?
3. What is the quality of reporting of equity-relevant
trials?
Phase 2, question 1: What are the strengths and limitations
of methods used in equity-relevant trials?
We will conduct a Cochrane methodology systematic re-
view to assess the strengths and limitations of methods
used to address equity in equity-relevant trials. A method-
ology review is different from an intervention review since
it aims to assess the strengths and limitations of methods
used for research rather than the impact of interventions.
For example, Welch and colleagues used a similar
approach to assess the strengths and limitations of
methods to assess equity in systematic reviews [33]. We
will develop an a priori protocol, following Cochrane
Handbook methods [34] and Cochrane Methodology
Review Group guidance [35]. The eligible studies will be
empirical studies of methods used in equity-relevant trials.
We have identified examples of eligible studies in Table 3.
We will design a search for evidence with a librarian sci-
entist (JM) encompassing electronic databases (e.g., MED-
LINE, The Cochrane Library, Cochrane Methodology
register, Sociological abstracts) and gray literature, using a
combination of text words and subject headings, and
assess its ability to identify a reference set of known arti-
cles (Appendix C). We will also use Web of Science to
search for studies that cite eligible studies [36]. The proto-
col will be submitted for publication in The Cochrane
Library. The results of this review will contribute candi-
date items for reporting equity-relevant trials.
Table 2 Examples of equity-relevant trials and those with no evidence about health equity
Type of trial Example RCT
1. Provides evidence of effects in a population
considered to be disadvantaged
A study of a classroom drama intervention for mental health of immigrant and refugee
youth in special classes [58].
A randomized controlled trial of community-led interventions to prevent domestic violence
in Aboriginal communities [59].
2. Provides evidence of difference or equivalence in
effects across socially stratifying factors
A study of sex differences in platelet reactivity and cardiovascular and psychological
response to mental stress in patients with stable ischemic heart disease [60].
A study of the impact of an informed choice invitation on uptake of screening for diabetes
in primary care assessed whether there were differences in effectiveness according to
socioeconomic status [61].
3. Provides evidence of a gradient of effects across
socially stratifying factors
A study of individual- and area-level unemployment influence smoking cessation among
African Americans [62].
4. Provides no evidence about equity Efficacy of the transillumination method for appropriate tracheal tube placement in small
children: a randomized controlled trial [63].
A comparison of cast materials for the treatment of congenital idiopathic clubfoot using
the Ponseti method [64].
Table 3 Examples of eligible studies for Cochrane systematic
review of methods to assess equity
1. Recruitment methods to engage disadvantaged populations in trials
• Study of the effect of incentive payments in 5 RCTs on recruitment
of ethnic minorities [65]
2. Reporting population characteristics
• Study of 100 RCTs in four leading medical journals assessed for
reporting of sociodemographic characteristics in “Table 1” [19]
3. Subgroup analyses
• Study of 169 cardiovascular RCTs for quality of reporting and
conducting sex/gender subgroup analyses [66]
4. Applicability of evidence
• Study of reasons for exclusion of participants from RCTs and effects
on applicability decisions [39]
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Phase 2, question 2: What is existing guidance on
conducting equity-relevant trials?
We will conduct a review of existing guidance for
equity-relevant trials such as inclusion of vulnerable
populations and ethical concerns. This will include guid-
ance developed by any type of organization, such as aca-
demic groups (e.g., CONSORT), funding agencies (e.g.,
NIH guidance on inclusion of women and minorities),
governmental and non-governmental organizations (e.g.,
Institute of Medicine guidance on sex-specific reporting
in research [37]), and the National Guidelines Clearing-
house (www.guideline.gov). We will design a search
strategy according to the Peer-Reviewed Electronic
Search Strategies (PRESS) guideline [36] that includes
both electronic databases and targeted search of websites
of relevant organizations with an experienced librarian
scientist (JM). Websites of organizations that provide
ethics guidance will be searched (e.g., Institute of Medi-
cine, Council for International Organizations of Medical
Sciences and World Association of Medical Editors), as
well as conducting open web searches.
Data will be extracted using a pretested form on the
methods of developing the guidance, values statements
(if provided), items related to study design, inclusion
and protection of different disadvantaged populations,
and any evidence on validation, uptake, or use of the
guidelines. We will assess the extent to which popula-
tions defined as disadvantaged across PROGRESS-Plus
criteria are considered in the guidance. The items iden-
tified by this review will be considered for inclusion in
CONSORT-equity.
Phase 2, question 3: What is the quality of reporting
equity-relevant trials?
We will conduct an empirical review of a random sam-
ple of published equity-relevant trials to assess methodo-
logical quality and reporting of equity considerations.
We will develop a search strategy for equity-relevant tri-
als, in collaboration with a librarian scientist (JM), using
both text words and MeSH headings, and test this
search with a reference set of equity-relevant trials. We
will search MEDLINE, Sociological abstracts, and Econ-
lit to encompass medical, public health, and inter-
national development interventions. We will restrict the
search to the last 3 years since reporting has improved
over time, and we expect a sufficient number of RCTs in
this period to meet our criteria. Two independent re-
viewers will screen titles and abstracts for eligibility
using the conceptual framework to identify equity-
relevant trials. We will select a random sample of 100
individually randomized trials and 100 cluster RCTs. We
decided to balance the sample according to cluster ver-
sus individual randomization to ensure an adequate
number of each design, because cluster RCTs have
unique equity considerations and because they may re-
quire different analysis strategies [38]. We will extract
data regarding the study design, populations, and ana-
lysis across PROGRESS-Plus characteristics using a pre-
tested data extraction form, with two independent
reviewers. We will assess reporting of methods using ac-
cepted criteria. For example, we will assess the extent to
which subgroup analyses meet criteria for credibility
[34]. We expect that the most commonly used methods
will be subgroup analyses, and if these are used by 25 %
of trials, each sample of 100 trials will provide a margin
of error of ±8.5 % around this proportion. We will de-
scribe the range of methods used to provide evidence
about equity (e.g., subgroup analysis, comparison of trial
populations with target population to judge external val-
idity [39]), any comparison between methods (if done),
and quality of reporting or conduct for specific methods
(e.g., quality of subgroup analyses). The results will be
used to identify candidate items for the CONSORT-
equity guideline.
Phase 3: To consult with global experts on candidate
items to improve reporting of equity-relevant trials
Health equity issues span a breadth of disciplinary fields
that may have different approaches to reporting trials.
Because we aim for broad relevance of this reporting
guideline, we want to seek opinions regarding how to
improve reporting of equity-relevant trials from different
disciplinary perspectives. We will conduct key inform-
ant, semi-structured interviews since this is an efficient
way to engage diverse stakeholders, and then collect and
synthesize their views using thematic analysis. We will
use results of the empirical studies (phase 2) to design a
semi-structured interview guide. The interview guide
will be designed to invite feedback on candidate items
identified in the prior studies as well as seeking new
items.
We will identify participants through our co-authors
and advisory board as well as lead authors of empirical
studies and other guidance (e.g., ethics, funding agen-
cies). We will select participants to maximize variation
of disciplines and stakeholder organizations (e.g., aca-
demic, non-governmental, research ethics boards, gov-
ernmental). We will conduct interviews by phone or
face to face and take notes during the interviews as well
as tape record interviews. We will expand our sample
by snowball sampling: an approach to recruit partici-
pants that builds on networks by asking each partici-
pant to suggest additional contacts [40]. Sample size
will be determined by theoretical saturation, defined as
when subsequent interviews contribute no new data,
and is estimated to occur at 10–13 interviews [41].
Thematic analysis of transcribed interviews will be con-
ducted by two coders, using NVivo qualitative software
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to facilitate analysis [42]. This portion of the study has
been submitted to the Bruyère Research Institute Ethics
Board for approval.
Phase 4: To prioritize candidate items for reporting
guideline
Prior to seeking consensus (phase 5), it is important to
seek external feedback on the importance of different can-
didate items identified in the preceding empirical studies
[25]. In this phase, we aim to prioritize items and invite
feedback on proposed items. We will use the Delphi
process for this prioritization because it is a structured,
iterative approach to obtaining information by posing a
series of questions to a select group of experts in the area
for which the information is sought [43]. To identify
participants, we will use electronic mailing lists and social
media to reach members of the intended users of the
reporting guideline, such as trialists, methodologists, clini-
cians, and decision-makers. Patient engagement and citi-
zen participation is critical from an equity perspective
since patients and citizens are the intended beneficiaries
of the results of trials. Patient and citizen views will be
sought by engaging with networks of patients and citizens
such as the Cochrane Consumer Network (led by AL,
who is the consumer representative on the Cochrane
Steering Group).
We will present a preliminary list of candidate items,
with examples, and ask participants to rank their import-
ance using an online survey tool. We will invite open-
ended comments and suggestions for new items. We plan
to conduct up to three rounds of an online Delphi survey,
as for previous CONSORT guidelines [44–46]. If consen-
sus is reached earlier, we will conduct fewer rounds of the
survey. This study has been submitted to the Bruyère
Research Institute Ethics Board for approval.
Phase 5: Consensus development
As recommended by Moher et al. [25], we will hold a 2-
day face-to-face consensus meeting to engage and build
consensus with users of the reporting guideline. We will
design this meeting to facilitate engagement and equit-
able opportunities for contributions from all conference
participants, by assigning roles as chairs, facilitators, dis-
cussants, and rapporteurs to each participant, as used
previously by Welch et al. [22]. Participants will include
members of the research team and advisory board and
may include other external stakeholders.
During the meeting, we will present the results for each
candidate item from the empirical studies and the Delphi
process with examples and use a structured discussion to
reach consensus on included items. The discussions will
be audio-recorded and transcribed verbatim. As with
other consensus meetings, word crafting will be left until
post-meeting. We will use meeting transcripts and notes
to finalize the CONSORT-equity reporting guideline.
Next, we will conduct an iterative process of usability
testing of the guideline by intended users to assess clar-
ity and acceptability of items. Written and oral feedback
from these users will be incorporated. Consensus group
members will participate in an iterative process of craft-
ing the final guideline. We will develop an elaboration
and explanation document with exemplars of good
reporting and details of empiric evidence to support
each item. This study has been submitted to the Bruyère
Research Institute Ethics Board for approval.
Phase 6: Dissemination and implementation
We will develop a knowledge translation (KT) plan at
the consensus conference, led by JMG, a known expert
in the area of implementation science and KT. We will
design strategies to promote implementation of the
reporting guideline by thought leaders who publish, use,
fund, or conduct RCTs across different disciplines. Pos-
sible strategies may include training workshops at events,
such as at the Cochrane Colloquia and the Peer Review
Congress, and webinars that will be made available on
open-access websites such as the Campbell and Cochrane
Equity Methods group website [47]. To reach journal edi-
tors and funders, we expect to use targeted approaches
such as direct letters with specific messages (e.g., how to
include this reporting guideline in instructions for authors
and applicants). Throughout the study, we will use infor-
mation technology to raise awareness, maintain a list of
publications, and invite comments through an open-
access website [48], writing blogs, and the use of social
media, including twitter [49].
Discussion
Following the WHO Commission on the Social De-
terminants of Health (CSDH), there is increasing
interest in health equity [17]. However, variable or
inadequate reporting of data from trials which can
inform health equity decisions could contribute to
waste in research and may not serve the needs of
people who are experiencing health inequities. This
program of research is the first known attempt to
improve the reporting of health equity in RCTs and
has been designed to complement current and in-
development CONSORT statement extensions. Im-
proved reporting of equity considerations is relevant
to health research funders, decision-makers, and
practitioners who use evidence from RCTs to inform
decisions, researchers conducting equity-oriented
systematic reviews, and civil society who benefit
from these decisions. We hope this reporting guide-
line will contribute to an improved evidence base for
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equity-oriented decisions and promote a broader
agenda in relation to health equity.
Appendix A: CONSORT standard items, selected
extensions, and possible CONSORT-equity items
Appendix B: CONSORT-equity advisory board
members
CONSORT-equity advisory board
1. Yvonne Boyer
Canada Research Chair in Aboriginal Health and
Wellness
Brandon University
2. Luis Gabriel Cuervo
Senior Advisor for Research Promotion and
Development, PAHO
3. Sarah Edwards
University College London
4. Caroline Kisia
Executive Director, Action Africa
Health-International
5. Anne Lydiatt
Patient partner, Canadian Institutes of Health
Research Strategy for Patient Oriented Research
6. Lawrence Mbuagbaw
Assistant Professor, Epidemiology and Biostatistics,
McMaster University
Centre for Development of Best Practices in Health,
Yaoundé Central Hospital, Cameroon
7. Janet Smylie
CIHR Applied Public Health Chair and Director,
Well Living House Action Research Centre for
Indigenous Infant, Child and Family Health and
Wellbeing, St. Michael’s Hospital and DLSPH,
University of Toronto
8. Jimmy Volmink
Dean, Centre for Evidence-Based Health Care, Fac-
ulty of Medicine and Health Sciences, Stellenbosch Uni-
versity and Cochrane South Africa, South African
Medical Research Council, Cape Town, South
Africa
9. Margaret Whitehead
WH Duncan Professor of Public Health, Division of
Public Health, School of Population, Community
and Behavioural Sciences, The University of
Liverpool
Appendix C: Search strategy to identify
equity-relevant trials
1. exp Gender Identity/
2. (gender-based or gender-related or gender
factors).tw.
3. ((sex or gender) adj3 (analysis or factor$ or inequit$
or disparit$ or inequalit$ or difference$ or
interact$)).mp. [mp=title, abstract, original title,
name of substance word, subject heading word,
keyword heading word, protocol supplementary
concept word, rare disease supplementary concept
word, unique identifier]
4. exp sex factors/
5. exp geriatrics/
6. ((ethnic$ or race or racial or religio$ or cultur$ or
minorit$ or refugee or indigenous or aboriginal or
African american) adj3 (analysis or disparit$ or
inequalit$ or inequit$ or difference$ or predict$ or
interact$)).tw.
7. exp homosexuality/
8. exp disabled persons/
9. ((poverty or low-income or “lower income” or socio-
economic$ or socio-economic or social) adj3
(analysis or disadvantage$ or factor$ or inequalit$ or
depriv$ or inequit$ or disparit$ or difference$ or
predict$ or interact$)).tw.
10. exp Educational Status/
11. exp Socioeconomic Factors/
12. ((discriminat$ or social exclu$ or social inclu$)
adj3 (religion or culture or race
or racial or aboriginal or indigenous or
ethnic$)).tw.
13. ((urban or rural or inner-city or remote or slum)
adj3 (analysis or inequit$ or disparit$ or inequalit$
or difference$ or predict$ or interact$)).tw.
Welch et al. Implementation Science  (2015) 10:146 Page 8 of 11
14. ((resource-poor or (“low income” adj countr$) or
(“middle income” adj countr$) or africa or
developing countr$ or “south america” or china or
asia or “latin america”) adj3 (relevance or analysis
or applicab$ or inequit$ or disparit$ or inequalit$
or difference$ or predict$ or interact$)).tw.
15. (inequalit$ or in-equalit or equit$ or inequit$ or
in-equit or disparit$ or underserved or
marginali$ed).tw.
16. exp indigenous populations/
17. ((native* or Indian or aborigin*) adj3 (American*
or Canadian* or Alaska*)).tw.
18. (first adj2 nation*).tw.
19. (aborigin$ or metis or inuit$ or eskimo$ or native
or esquimaux or aleut or yuit or inughuit or
unanga* or alutiiq or inup#ia* or kalaallit or
Inuktitut or Nunavut or nunavik or cree or dene or
haida or salish or Mohawk or ojibway or yupik or
tribal or arctic).tw.
20. exp american native continental ancestry group/ or
oceanic ancestry group/
21. exp rural health/
22. or/1–21
23. randomized controlled trial.pt.
24. (randomized or placebo).mp.
25. (cluster$ adj2 randomi$).tw.
26. or/23–25
27. 22 and 26
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